IBD-0333

N/A

Report date: 2025/01/18 20:00:05

Base Information

Drug NameIBD-0333

Drug Alias NameIBD-0333IBD0333

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 stimulantsSignal transducer CD24 stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4]

TargetsTumor necrosis factor receptor superfamily member 9Signal transducer CD24

Therapy Area/IndicationsSolid tumoursLymphoma, Non-HodgkinNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesSunHo (China) BioPharmaceutical Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSunHo (China) BioPharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursLymphoma, Non-Hodgkin

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A